Cargando…
Management of Multiple Sclerosis in the Breastfeeding Mother
Multiple Sclerosis (MS) is an autoimmune neurological disease characterized by inflammation of the brain and spinal cord. Relapsing-Remitting MS is characterized by acute attacks followed by remission. Treatment is aimed at halting these attacks; therapy may last for months to years. Because MS disp...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757692/ https://www.ncbi.nlm.nih.gov/pubmed/26966579 http://dx.doi.org/10.1155/2016/6527458 |
_version_ | 1782416491649433600 |
---|---|
author | Almas, Saneea Vance, Jesse Baker, Teresa Hale, Thomas |
author_facet | Almas, Saneea Vance, Jesse Baker, Teresa Hale, Thomas |
author_sort | Almas, Saneea |
collection | PubMed |
description | Multiple Sclerosis (MS) is an autoimmune neurological disease characterized by inflammation of the brain and spinal cord. Relapsing-Remitting MS is characterized by acute attacks followed by remission. Treatment is aimed at halting these attacks; therapy may last for months to years. Because MS disproportionately affects females and commonly begins during the childbearing years, clinicians treat pregnant or nursing MS patients. The intent of this review is to perform an in-depth analysis into the safety of drugs used in breastfeeding women with MS. This paper is composed of several drugs used in the treatment of MS and current research regarding their safety in breastfeeding including immunomodulators, immunosuppressants, monoclonal antibodies, corticosteroids, and drugs used for symptomatic treatment. Typically, some medications are large polar molecules which often do not pass into the milk in clinically relevant amounts. For this reason, interferon beta is likely safe for the infant when given to a breastfeeding mother. However, other drugs with particularly dangerous side effects may not be recommended. While treatment options are available and some data from clinical studies does exist, there continues to be a need for investigation and ongoing review of the medications used in breastfeeding mothers. |
format | Online Article Text |
id | pubmed-4757692 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Hindawi Publishing Corporation |
record_format | MEDLINE/PubMed |
spelling | pubmed-47576922016-03-10 Management of Multiple Sclerosis in the Breastfeeding Mother Almas, Saneea Vance, Jesse Baker, Teresa Hale, Thomas Mult Scler Int Review Article Multiple Sclerosis (MS) is an autoimmune neurological disease characterized by inflammation of the brain and spinal cord. Relapsing-Remitting MS is characterized by acute attacks followed by remission. Treatment is aimed at halting these attacks; therapy may last for months to years. Because MS disproportionately affects females and commonly begins during the childbearing years, clinicians treat pregnant or nursing MS patients. The intent of this review is to perform an in-depth analysis into the safety of drugs used in breastfeeding women with MS. This paper is composed of several drugs used in the treatment of MS and current research regarding their safety in breastfeeding including immunomodulators, immunosuppressants, monoclonal antibodies, corticosteroids, and drugs used for symptomatic treatment. Typically, some medications are large polar molecules which often do not pass into the milk in clinically relevant amounts. For this reason, interferon beta is likely safe for the infant when given to a breastfeeding mother. However, other drugs with particularly dangerous side effects may not be recommended. While treatment options are available and some data from clinical studies does exist, there continues to be a need for investigation and ongoing review of the medications used in breastfeeding mothers. Hindawi Publishing Corporation 2016 2016-02-04 /pmc/articles/PMC4757692/ /pubmed/26966579 http://dx.doi.org/10.1155/2016/6527458 Text en Copyright © 2016 Saneea Almas et al. https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Almas, Saneea Vance, Jesse Baker, Teresa Hale, Thomas Management of Multiple Sclerosis in the Breastfeeding Mother |
title | Management of Multiple Sclerosis in the Breastfeeding Mother |
title_full | Management of Multiple Sclerosis in the Breastfeeding Mother |
title_fullStr | Management of Multiple Sclerosis in the Breastfeeding Mother |
title_full_unstemmed | Management of Multiple Sclerosis in the Breastfeeding Mother |
title_short | Management of Multiple Sclerosis in the Breastfeeding Mother |
title_sort | management of multiple sclerosis in the breastfeeding mother |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4757692/ https://www.ncbi.nlm.nih.gov/pubmed/26966579 http://dx.doi.org/10.1155/2016/6527458 |
work_keys_str_mv | AT almassaneea managementofmultiplesclerosisinthebreastfeedingmother AT vancejesse managementofmultiplesclerosisinthebreastfeedingmother AT bakerteresa managementofmultiplesclerosisinthebreastfeedingmother AT halethomas managementofmultiplesclerosisinthebreastfeedingmother |